Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 21;9(6):e002323. doi: 10.1136/jitc-2020-002323

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Activated OX40 +PD-1− T cells in the R2-GDP-GOTEL clinical trial. (A) Cell concentrations before treatment compared with HD; (B) evolution of activated T cells during B, C3 and EOI involving all patients recruited; (C) evolution of activated CD4+ T cells in patients with OS >24 months and OS <24 months during B, C3 and EOI; (D) evolution of activated CD8 +T cells in patients with OS >24 months and OS <24 months during B, C3 and EOI; (E) evolution of total activated T cells in patients with OS >24 months and OS <24 months during B, C3 and EOI. All data shown are medians and 95% CIs of cells/L. #P≤0.05, ##p≤0.01, ###p≤0.001 comparing opposite subject groups, respectively; *p≤0.05, **p≤0.01 compared with basal, respectively. EOI, end of induction; GOTEL, Spanish Lymphoma Oncology Group; HD, healthy donors; OS, overall survival; R2-GDP, rituximab, gemcitabine, dexamethasone, and cisplatin; R/R DLBCL, relapsed/refractory diffuse large B-cell lymphoma.